Soricimed Biopharma Inc.

Soricimed Biopharma Inc. is a Canadian biotechnology firm focused on developing innovative peptide-based cancer therapies targeting solid tumors through its proprietary TRPV6-targeting platform. Founded in 2005, Soricimed Biopharma Inc. specializes in the development of targeted treatments for oncology.

The company is led by CEO Robert Bruce and was originally founded by John Stewart. Soricimed is headquartered in Canada and has raised a total of USD 0. 25 mn, with the most recent funding round occurring in March 2017, led by New Brunswick Innovation Foundation. The company has completed a total of 2 deals.

Soricimed Biopharma specializes in a proprietary platform harnessing TRPV6-targeting peptides to develop highly targeted treatments for various solid tumors. Their main product, SOR-C13, is designed to selectively bind to TRPV6, a calcium channel overexpressed in solid tumor cells, facilitating the targeted delivery of therapeutic agents. This innovative approach addresses critical challenges in oncology, including tumor growth, metastasis, and resistance to programmed cell death. The company's peptide-drug conjugate platform further enhances the efficacy of anticancer treatments by acting as delivery vectors for other therapeutic payloads.

Soricimed primarily serves oncology-focused healthcare providers and researchers, aiming to penetrate markets in North America and Europe, where the demand for innovative cancer therapies is substantial. Soricimed Biopharma operates through a model that includes partnerships and collaborations for the development and commercialization of its therapies. Transactions typically involve agreements with healthcare institutions and research organizations for the clinical testing and application of their products, such as SOR-C13. The structure of these transactions may include milestone payments tied to research and development progress, as well as potential future royalties from successful commercialization.

While specific pricing plans for their offerings are not disclosed, the focus on B2B relationships indicates that their revenue generation strategy is rooted in strategic partnerships aimed at advancing their targeted therapies into clinical practice. The company’s revenue relies on its unique position in the oncology market, supported by its proprietary technology and scientific advancements. Soricimed Biopharma aims to leverage the USD 0. 25 mn raised in March 2017 to support the advancement of its pipeline, focusing on the development of SOR-C13 and other products within their TRPV6-targeting platform.

The company is looking to expand its reach into North America and Europe with an emphasis on oncology markets. Future product launches are anticipated as part of this strategy, although specific timelines and details on new products have yet to be disclosed.